NCT03012230View on ClinicalTrials.gov

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

January 6, 2023

Study Completion Date

March 8, 2023

Conditions
Metastatic Malignant Neoplasm in the BoneStage IV Breast Cancer AJCC v6 and v7Triple-Negative Breast Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Ruxolitinib Phosphate

Given PO

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03012230 - Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter